secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001787306-23-000068
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Biotherapeutics shareholders re-elect three Class II directors, ratify EY, approve say-on-pay
--------------------------------------------------------------------------------

- All three Class II directors elected: Heron (44.2M for), Krishnamohan (50.4M for), Watanabe (45.4M for).
- Ratification of Ernst & Young as independent auditor for FY 2023 passed with 54.5M votes for, 358K against.
- Non-binding advisory vote on named executive officer compensation approved with 43.8M for, 7.3M against.
- Meeting held May 31, 2023; record date April 3, 2023 with 61,360,936 shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/arqt-20230602.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer